New Zealand markets open in 1 hour 46 minutes

Atossa Therapeutics, Inc. (YAG2.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.4200-0.0380 (-2.61%)
At close: 08:00AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 181.68M
Enterprise value 104.42M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.32
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.88

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3120.91%
S&P500 52-week change 326.49%
52-week high 32.1350
52-week low 30.5770
50-day moving average 31.4422
200-day moving average 30.9208

Share statistics

Avg vol (3-month) 33.31k
Avg vol (10-day) 37k
Shares outstanding 5125.76M
Implied shares outstanding 6127.88M
Float 8117.91M
% held by insiders 10.06%
% held by institutions 121.65%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 320 Apr 2018

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-18.85%
Return on equity (ttm)-29.84%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -31.23M
Net income avi to common (ttm)-29.69M
Diluted EPS (ttm)-0.2200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)83.96M
Total cash per share (mrq)0.67
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)16.34
Book value per share (mrq)0.68

Cash flow statement

Operating cash flow (ttm)-18.62M
Levered free cash flow (ttm)-8.62M